Risk factors
Karyopharm Therapeutics (KPTI) risk factors
Item 1A of every Karyopharm Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors74 risks13 new7 dropped21 reworded
Karyopharm faces severe going concern doubts, with cash runway only into the second quarter of 2026.
Filed Feb 13, 2026 - FY2024 10-K risk factors68 risks
Karyopharm faces substantial going concern doubt with an accumulated deficit of $1.6 billion and net loss of $76.4 million in 2024. The company carries significant indebtedness totaling hundreds of millions across 2025 Notes, 2029 Notes, and an Amended Revenue Interest Agreement. Operations depend heavily on the successful commercialization and patent exclusivity of XPOVIO in hematological malignancies.
Filed Feb 19, 2025